HealthNotableConfirmedDeveloping
5.6
Ireland's HSE to decide on reimbursement for €280k-a-year Friedreich's ataxia drug Skyclarys
The JournalLO·IE·about 8 hours ago
Campaigners are demonstrating in Dublin to pressure the Health Service Executive (HSE) to approve reimbursement for Skyclarys, a treatment for Friedreich's Ataxia. The outcome of the reimbursement decision remains uncertain, impacting patient access to the therapy in Ireland.